What type of study is this?

This is a Cohort Study study (also classified as: Human Clinical Trial).

September 24, 2025Open Access

OX40/OX40L: A New Target for Tumor Immunotherapy and Its Clinical Research Progress

View Full Paper

Ask AI

Bookmark

Authors

This review demonstrates OX40L's role in enhancing immune responses in cancers, highlighting clinical trials and therapeutic potential.

Activation of T cells through OX40L binding promotes antitumor immune responses and cytokine production.
Clinical trials involving OX40 agonists indicate a potential reduction in tumor progression and positive safety profiles.
Current OX40 agonist antibodies are in early phase I/II studies, exhibiting good tolerability and therapeutic promise.
The review addresses limitations in existing therapies, proposing strategies to improve OX40-targeted treatment approaches.

Yuan et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark